MARKET

AMRX

AMRX

AMNEAL PHARMACEU
NYSE

Real-time Quotes | Nasdaq Last Sale

4.930
-0.020
-0.40%
Closed 16:59 07/29 EDT
OPEN
5.02
PREV CLOSE
4.950
HIGH
5.07
LOW
4.860
VOLUME
665.21K
TURNOVER
--
52 WEEK HIGH
7.45
52 WEEK LOW
3.450
MARKET CAP
1.48B
P/E (TTM)
-41.6385
1D
5D
1M
3M
1Y
5Y
10 Best Medical Stocks Under $10
In this article, we will take a look at the 10 best medical stocks under $10. You can skip our detailed analysis of the healthcare industry, and go directly to the 5 Best Medical Stocks Under $10. While the COVID-19 virus spread worldwide, the medical indu...
Insider Monkey · 4d ago
Hot Stocks: Earnings move IBM, HCA, PPG; FDA decisions prompt gains in AMRX, steep losses in ARDX
Pgiam/iStock via Getty Images Earnings reports dominated the headlines on Tuesday. IBM (IBM) and HCA Healthcare (HCA) both gained ground in pre-market action following their quarterly releases. PPG Industries (PPG)
Seekingalpha · 07/20 13:06
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19)
Benzinga · 07/20 12:19
Amneal wins approval for generic TobraDex
RealPeopleGroup/E+ via Getty Images The FDA has approved an ANDA from Amneal Pharmaceuticals ([[AMRX]] +0.2%) for a generic of TobraDex (dexamethasone and tobramycin ophthalmic suspension). The drug is indicated for for
Seekingalpha · 07/19 21:02
Amneal Gets ANDA Approval From FDA for Generic TobraDex, Shares Higher
marketwatch.com · 07/19 20:46
BRIEF-Amneal Receives Approval For Generic Tobradex®
reuters.com · 07/19 20:35
Amneal Pharmaceuticals Says Receives Approval For Generic TobraDex
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) ("Amneal" or the "Company") today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration
Benzinga · 07/19 20:33
Amneal Pharmaceuticals Receives FDA Approval for TobraDex Generic Version
MT Newswires · 07/19 16:51
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AMRX. Analyze the recent business situations of AMNEAL PHARMACEU through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AMRX stock price target is 6.93 with a high estimate of 9.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 235
Institutional Holdings: 125.32M
% Owned: 41.66%
Shares Outstanding: 300.84M
TypeInstitutionsShares
Increased
40
12.60M
New
47
9.23M
Decreased
46
16.84M
Sold Out
17
1.52M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.26%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Non-Executive Chairman/Independent Director
Paul Meister
President/Co-Chief Executive Officer/Co-Founder/Director
Chirag Patel
Co-Chief Executive Officer/Co-Founder/Director
Chintu Patel
Chief Financial Officer/Executive Vice President/IR Contact Officer
Anastasios Konidaris
Chief Human Resource Officer/Executive Vice President
Nikita Shah
Executive Vice President
Andrew Boyer
Executive Vice President
Joseph Todisco
Senior Vice President/General Counsel/Secretary
Stephen Manzano
Director
Emily Alva
Director
Gautam Patel
Independent Director
J. Kevin Buchi
Independent Director
Jeffrey George
Independent Director
John Kiely
Independent Director
Ted Nark
Independent Director
Shlomo Yanai
No Data
About AMRX
Amneal Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the developing, manufacturing, marketing and distributing high-value generic and branded specialty pharmaceutical products across a broad array of dosage forms and therapeutic areas. It operates in three segments, which include Generics, Specialty and AvKARE. The Generics segment provides prescription pharmaceutical products. The Specialty Pharma is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system (CNS) disorders. AvKARE segment provides pharmaceuticals, medical and surgical products and services to governmental agencies. Its other pipeline includes 505(b)(2) drugs and complex generics.

Webull offers kinds of Amneal Pharmaceuticals Inc stock information, including NYSE:AMRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AMRX stock methods without spending real money on the virtual paper trading platform.